Primary prevention of Clostridium difficile infections with a specific probiotic combining Lactobacillus acidophilus, L. casei, and L. rhamnosus strains: assessing the evidence

Journal of Hospital Infection

Volumn 99, Issue 4, 2018, Pages 443-452

  McFarland, L V ^a   Ship, N ^b   Auclair, J ^b   Millette, M ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Bio K+ International Inc   (Canada)

Author keywords

Clostridium difficile; Lactobacilli probiotics; Prevention

Indexed keywords

ANTIBIOTIC AGENT; PROBIOTIC AGENT;

BACTERIAL STRAIN; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; HEALTHCARE ASSOCIATED INFECTION; HUMAN; INCIDENCE; INTESTINE FLORA; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS CASEI; LACTOBACILLUS RHAMNOSUS; PEPTOCLOSTRIDIUM DIFFICILE; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK FACTOR; CLOSTRIDIUM INFECTION; GROWTH, DEVELOPMENT AND AGING; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

CLOSTRIDIUM INFECTIONS; HUMANS; INCIDENCE; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS CASEI; LACTOBACILLUS RHAMNOSUS; PRIMARY PREVENTION; PROBIOTICS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 85048585662     PISSN: 01956701     EISSN: 15322939     Source Type: Journal    
DOI: 10.1016/j.jhin.2018.04.017     Document Type: Review

References (69)

1. Magill, S.S., Edwards, J.R., Bamberg, W., Beldavs, Z.G., Dumyati, G., Kainer, M.A., et al. Multistate point-prevalence survey of health care-associated infections. N Engl J Med 370 (2014), 1198–1208.
2. Leffler, D.A., Lamont, J.T., Clostridium difficile infection. N Engl J Med 372 (2015), 1539–1548.
3. Shen, A., A gut odyssey: the impact of the microbiota on Clostridium difficile spore formation and germination. PLoS Pathog, 11, 2015, e1005157.
4. Dubberke, E.F., Reske, K.A., Noble-Wang, J., Thompson, A., Killgore, G., Mayfield, J., et al. Prevalence of C. difficile environmental contamination and strain variability in multiple health care facilities. Am J Infect Control 35 (2007), 315–318.
5. McFarland, L.V., What's lurking under the bed? Persistence and predominance of particular Clostridium difficile strains in a hospital and the potential role of environmental contamination. Infect Control Hosp Epidemiol 23 (2002), 639–640.
6. McFarland, L.V., Mulligan, M.E., Kwok, R.Y.Y., Stamm, W.E., Nosocomial acquisition of Clostridium difficile infection. N Engl J Med 320 (1989), 204–210.
7. Chang, V.T., Nelson, K., The role of physical proximity in nosocomial diarrhea. Clin Infect Dis 31 (2000), 717–722.
8. Jullian-Desayes, I., Landelle, C., Mallaret, M.R., Brun-Buisson, C., Barbut, F., Clostridium difficile contamination of health care workers’ hands and its potential contribution to the spread of infection: review of the literature. Am J Infect Control 45 (2017), 51–58.
9. McFarland, L.V., Ozen, M., Dinleyici, E.C., Goh, S., Comparison of pediatric and adult antibiotic-associated diarrhea and Clostridium difficile infections. World J Gastroenterol 22 (2016), 3078–3104.
10. Evans, C.T., Safdar, N., Current trends in the epidemiology and outcomes of Clostridium difficile infection. Clin Infect Dis 60:Suppl 2 (2015), S66–S71.
11. Minalyan, A., Gabrielyan, L., Scott, D., Jacobs, J., Pisegna, J.R., The gastric and intestinal microbiome: role of proton pump inhibitors. Curr Gastroenterol Rep, 19, 2017, 42.
12. Abt, M.C., McKenney, P.T., Pamer, E.G., Clostridium difficile colitis: pathogenesis and host defence. Nature Rev Microbiol 14 (2016), 609–620.
13. Chandrasekaran, R., Lacy, D.B., The role of toxins in Clostridium difficile infection. FEMS Microbiol Rev 41 (2017), 723–750.
14. Lessa, F.C., Winston, L.G., McDonald, L.C., Emerging Infections Program C. difficile Surveillance Team. Burden of Clostridium difficile infection in the United States. N Engl J Med 372 (2015), 2369–2370.
15. Abou Chakra, C.N., McGeer, A., Labbé, A.C., Simor, A.E., Gold, W.L., Muller, M.P., et al. Factors associated with complications of Clostridium difficile infection in a multicenter prospective cohort. Clin Infect Dis 61 (2015), 1781–1788.
16. Loo, V.G., Poirier, L., Miller, M.A., Oughton, M., Libman, M.D., Michaud, S., et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 353 (2005), 2442–2449.
17. McFarland, L.V., Therapies on the horizon for Clostridium difficile infections. Expert Opin Invest Drugs 25 (2016), 541–555.
18. Lytvyn, L., Mertz, D., Sadeghirad, B., Alaklobi, F., Selva, A., Alonso-Coello, P., et al. Prevention of Clostridium difficile infection: a systematic survey of clinical practice guidelines. Infect Control Hosp Epidemiol 37 (2016), 901–908.
19. Deyneko, A., Cordeiro, F., Berlin, L., Ben-David, D., Perna, S., Longtin, Y., Impact of sink location on hand hygiene compliance after care of patients with Clostridium difficile infection: a cross-sectional study. BMC Infect Dis, 16, 2016, 203.
20. Martin, M., Zingg, W., Knoll, E., Wilson, C., Dettenkofer, M., PROHIBIT Study Group. National European guidelines for the prevention of Clostridium difficile infection: a systematic qualitative review. J Hosp Infect 87 (2014), 212–219.
21. Chopra, T., Goldstein, E.J.C., C. difficile infection in long-term care facilities: a call to action for antimicrobial stewardship. Clin Infect Dis 60:Suppl 2 (2015), S73–S76.
22. Varughese, C.A., Vakil, N.H., Phillips, K.M., Antibiotic-associated diarrhea: a refresher on causes and possible prevention with probiotics – continuing education article. J Pharm Pract 26 (2013), 476–482.
23. McFarland, L.V., From yaks to yogurt: the history, development and current use of probiotics. Clin Infect Dis 60:Suppl 2 (2015), S85–S90.
24. Spinler, J.K., Ross, C.L., Savidge, T.C., Probiotics as adjunctive therapy for preventing Clostridium difficile infection – what are we waiting for?. Anaerobe 41 (2016), 51–57.
25. Goldenberg, J.Z., Yap, C., Lytvyn, L., Lo, C.K., Beardsley, J., Mertz, D., et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev(12), 2017, CD006095.
26. Hill, C., Guarner, F., Reid, G., Gibson, G.R., Merenstein, D.J., Pot, B., et al. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol 11 (2014), 506–514.
27. Goldstein, E.J., Tyrrell, K.L., Citron, D.M., Lactobacillus species: taxonomic complexity and controversial susceptibilities. Clin Infect Dis 60:Suppl 2 (2015), S98–S107.
28. Grzeskowiac, L., Isolauri, I., Salminen, S., Gueimonde, M., Manufacturing process influences properties of probiotic bacteria. Br J Nutr 105 (2011), 887–894.
29. Auclair, J., Frappier, M., Millette, M., Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R, and Lactobacillus rhamnosus CLR2 (Bio-K+): characterization, manufacture, mechanisms of action, and quality control of a specific probiotic combination for primary prevention of Clostridium difficile infection. Clin Infect Dis 60:Suppl 2 (2015), S135–S143.
30. Goldstein, E.J.C., Johnson, S., Maziade, P.J., McFarland, L.V., Trick, W., Dresser, L., et al. Pathway to prevention of nosocomial C. difficile infection. Clin Infect Dis 60:Suppl 2 (2015), S148–S158.
31. McFarland, L.V., Probiotics for the primary and secondary prevention of C. difficile infections: a meta-analysis and systematic review. Antibiotics 4 (2015), 160–178.
32. Graul, T., Cain, A.M., Karpa, K.D., Lactobacillus and bifidobacteria combinations: a strategy to reduce hospital-acquired Clostridium difficile diarrhea incidence and mortality. Med Hypoth 73 (2009), 194–198.
33. Pirker, A., Stockenhuber, A., Remely, M., Harrant, A., Hippe, B., Kamhuber, C., et al. Effects of antibiotic therapy on the gastrointestinal microbiota and the influence of Lactobacillus casei. Food Agric Immunol 24 (2013), 315–330.
34. Flatley, E.A., Wilde, A.M., Nailor, M.D., Saccharomyces boulardii for the prevention of hospital onset Clostridium difficile infection. J Gastrointest Liver Dis 24 (2015), 21–24.
35. Kujawa-Szewieczek, A., Adamczak, M., Kwiecień, K., Dudzicz, S., Gazda, M., Więcek, A., The effect of Lactobacillus plantarum 299v on the incidence of Clostridium difficile infection in high risk patients treated with antibiotics. Nutrients 7 (2015), 10179–10188.
36. Berry, A.C., Learned, M., Garland, J., Berry, L., Rodriguez, S., Scott, B., et al. Intensive care unit probiotic utilization rates: when committee recommendations and physician utilization diverge. Infect Control Hosp Epidemiol 38 (2017), 1011–1013.
37. Olson, B., Floyd, R.A., Howard, J., Hassanein, T., Warm, K., Oen, R., A multipronged approach to decrease the risk of C. difficile infection at a community hospital and long-term care facility. J Clin Outcomes Manage 22 (2015), 398–406.
38. Cruz-Betancourt, A., Cooper, C.D., Sposato, K., Milton, H., Louzon, P., Pepe, J., et al. Effects of a predictive preventive model for prevention of C. difficile infection in patients in intensive care units. Am J Infect Control 44 (2016), 421–424.
39. Millette, M., Luquet, F.M., Ruiz, M.T., Lacroix, M., Characterization of probiotic properties of Lactobacillus strain. Dairy Sci Technol 88 (2008), 695–705.
40. Millette, M., Nguyen, A., Amine, K.M., Lacroix, M., Gastrointestinal survival of bacteria in commercial probiotic products. Int J Probiot Prebiot 8 (2013), 149–156.
41. United States Pharmacopeia (USP) Edition 2005. Section 701. Disintegration, USP 29, p. 2411. Available at: http://www.usp.org/sites/defailut/files/asp/document/hormonization/gen-methods/q02_pf_31_1_2005.pdf [last accessed January 2018].
42. Aroutcheva, A., Auclair, J., Frappier, M., Millette, M., Lolans, K., de Montigny, D., et al. Importance of molecular methods to determine whether a probiotic is the source of Lactobacillus bacteremia. Probiot Antimicrob Prot 8 (2016), 31–40.
43. Beausoleil, M., Fortier, N., Guénette, S., L'ecuyer, A., Savoie, M., Franco, M., et al. Effect of a fermented milk combining Lactobacillus acidophilus Cl1285 and Lactobacillus casei in the prevention of antibiotic-associated diarrhea: a randomized, double-blind, placebo-controlled trial. Can J Gastroenterol 21 (2007), 732–736.
44. Sampalis, J., Psaradellis, E., Rampakakis, E., Efficacy of BIO K+ CL1285 in the reduction of antibiotic-associated diarrhea – a placebo controlled double-blind randomized, multi-center study. Archs Med Sci 6 (2010), 56–64.
45. Gao, X.W., Mubasher, M., Fang, C.Y., Reifer, C., Miller, L.E., Dose–response efficacy of a proprietary probiotic formula of Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R for antibiotic-associated diarrhea prophylaxis in adult patients. Am J Gastroenterol 105 (2010), 1636–1641.
46. Bermudez-Brito, M., Plaza-Díaz, J., Muñoz-Quezada, S., Gómez-Llorente, C., Gil, A., Probiotic mechanisms of action. Ann Nutr Metab 61 (2012), 160–174.
47. McFarland, L.V., Use of probiotics to correct dysbiosis of normal microbiota following disease or disruptive events: a systematic review. BMJ Open, 4, 2014, e005047.
48. Millette, M., Luquet, F.M., Lacroix, M., In vitro growth control of selected pathogens by Lactobacillus acidophilus and Lactobacillus casei-fermented milk. Lett Appl Microbiol 44 (2007), 314–319.
49. Karska-Wysocki, B., Bazo, M., Smoragiewicz, W., Antibacterial activity of Lactobacillus acidophilus and Lactobacillus casei against methicillin-resistant Staphylococcus aureus (MRSA). Microbiol Res 165 (2010), 674–686.
50. rd, 2017.
51. st, 2012.
52. Qa'Dan, M., Spyres, L.M., Ballard, J.D., pH-induced conformational changes in Clostridium difficile toxin B. Infect Immun 68 (2000), 2470–2474.
53. Pepin, J., Alary, M.E., Valiquette, L., Raiche, E., Ruel, J., Fulop, K., et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis 40 (2005), 1591–1597.
54. Kamdeu-Fansi, A.A., Guertin, J.R., LeLorier, J., Savings from the use of a probiotic formula in the prophylaxis of antibiotic-associated diarrhea. J Med Econ 15 (2012), 53–60.
55. McFarland, L.V., An observation on inappropriate probiotic subgroup classifications in the meta-analysis by Lau and Chamberlain. Int J Gen Med 9 (2016), 333–336.
56. McDonald, L.C., Gerding, D.N., Johnson, S., Bakken, J.S., Carroll, K.C., Coffin, S.E., et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis 66 (2018), e1–e48.
57. ®. Poster presented at the Annual Conference of the Canadian Society of Gastroenterology Nurses and Associates. September 29–30, 2016, Winnipeg, MB, Canada.
58. Maziade, P.J., Andriessen, J.A., Pereira, P., Currie, B., Goldstein, E.J.C., Impact of adding prophylactic probiotics to a bundle of standard preventative measures for C. difficile infection: enhanced and sustained decrease in the incidence and severity of infection at a community hospital. Curr Med Res Opin 29 (2013), 1341–1347.
59. Maziade, P.J., Pereira, P., Goldstein, E.J.C., A decade of experience in primary prevention of C. difficile infection at a community hospital using the probiotic combination L. acidophilus CL1285, L. casei LBC80R and L. rhamnosus CLR2 (Bio-K+). Clin Infect Dis 60:Suppl 2 (2015), S144–S147.
60. Trick, W.E., Sokalski, S.J., Johnson, S., Bunnell, K.I., Levato, J., Ray, M.J., et al. Effectiveness of probiotic for primary prevention of Clostridium difficile infection: A single-center before-and-after quality improvement intervention at a tertiary-care medical center. Infect Control Hosp Epidemiol, 2018, 1–6 Epub.
61. Bussieres, M., L'Esperance, S., Coulombe, M., Rhainds, M., Unite d'evaluation des technologies et des modes d'intervention en sante du CHU de Quebec (UETMIS-CHU de Quebec). Utilisation des probiotiques pour prevenir les diarrhees associees aux antibiotiques et au Clostridium difficile chez l'adulte hospitalize. [Use of probiotics for the prevention of antibiotic-associated diarrhea and C. difficile in adult inpatients.] Rapport d'evaluation UETMIS 03-14, Quebec. XI, 2014, 1–75 Available at: www.chuq.qc.ca/fr/evaluation.
62. st, 2015.
63. th, 2017.
64. Sanders, M.E., Merenstein, D.J., Ouwehand, A.C., Reid, G., Salminen, S., Cabana, M.D., et al. Probiotic use in at-risk populations. J Am Pharm Assoc 56 (2016), 680–686.
65. Salminen, M.K., Tynkkynen, S., Rautelin, H., Saxelin, M., Vaara, M., Ruutu, P., et al. Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland. Clin Infect Dis 35 (2002), 1155–1160.
66. Boumis, E., Capone, A., Galati, V., Venditti, C., Petrosillo, N., Probiotics and infective endocarditis in patients with hereditary hemorrhagic telangiectasia: a clinical case and a review of the literature. BMC Infect Dis 18 (2018), 65–72.
67. Natural Health Products of Canada. Available at: https://www.canada.ca/en/health-canada/services/drugs-health-products/natural-non-prescription/regulation.html [last accessed January 2018].
68. Allen, S.J., Wareham, K., Wang, D., Bradley, C., Sewell, B., Hutchings, H., et al. A high-dose preparation of lactobacilli and bifidobacteria in the prevention of antibiotic-associated and Clostridium difficile diarrhoea in older people admitted to hospital: a multicentre, randomised, double-blind, placebo-controlled, parallel arm trial (PLACIDE). Health Technol Assess 17 (2013), 1–140.
69. Louh, I.K., Greendyke, W.G., Hermann, E.A., Davidson, K.W., Falzon, L., Vawdrey, D.K., et al. Clostridium difficile infection in acute care hospitals: systematic review and best practices for prevention. Infect Control Hosp Epidemiol 38 (2017), 476–482.